Recruiting
Primary Outcome Measures Time to Diagnosis Hospitalization time Secondary Outcome Measures Patient’s discomfort/pain Complications Rate of Non Specific Pleuritis Inclusion Criteria Undiagnosed pleural effusion with the character of a lymphocytic exudate Exclusion Criteria Empyema Transudate pleural effusion. Central airway obstruction by tumor. Existence of extensive adhesions that do not allow the development of iatrogenic pneumothorax…
Primary Outcome Measures Number of Patients who Experience Dose-Limiting Toxicity Number of patients who experience a treatment-related adverse event Objective response rate (ORR) Duration of response (DOR) Progression free survival (PFS) Overall survival (OS) Secondary Outcome Measures Area under the plasma concentration versus time curve (AUC) Time to achieve maximal plasma concentration (Tmax) Maximum observed…
Primary Outcome Measures Acute Radiation Toxicity late radiation toxicity Inclusion Criteria Evidence of metastatic disease. Underwent Pleural decortication. Able to provide informed consent. Exclusion Criteria Poor pulmonary function tests. Recurrent or palliative cases. Inability to attend full course of Radiotherapy or follow up visits.
Primary Outcome Measures Diagnostic Performance Secondary Outcome Measures Location biopsy Staging Patient Management Uptake Values Changes uptake parameters due to anticancer treatment Correlate immunohistochemistry Incidental findings Safety Evaluation FAPI-injection Overall survival Recurrence/Progression Free Survival Response evaluation Interobserver reliability Inclusion Criteria Patients with pleural lesions suspicious of pleural mesothelioma and referred to pleural biopsy. Undergone/undergoing FDG…
Primary Outcome Measures the comparison of prevalence of germline mutations in MPM patients vs asbestos exposed healthy subjects Secondary Outcome Measures Secondary aim will be the comparison of overall survival (OS) according to mutational status in MPM patients. Inclusion Criteria Inclusion Criteria Cohort A: Patient with a documented diagnosis of MPM (any disease stage and…
Primary Outcome Measures The diagnostic performance (sensitivity, specificity, positive predicative value, negative predicative value, and overall diagnostic accuracy – all parameters in %). in of FAPI PET compared to routine imaging modalities, including FDG PET/CT, in suspected PM lesions. Secondary Outcome Measures Calculate the proportion of patients where the location of the intended pleural biopsy…
Primary Outcome Measures Calculate the proportion of patients where the location of the intended pleural biopsy is altered due to FAPI PET/CT replacing FDG PET/CT. Secondary Outcome Measures Compare the cancer stage (IASCL 9th edition TNM-classification) as determined by FAPI PET/CT compared to conventional imaging (including FDG PET/CT) at primary staging. Calculate the proportion of…
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli – IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4’s role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.
It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.
